# Don L. Gibbons

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/don-l-gibbons/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,594 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 83 |
| i10-index | 222 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5010884206 |
| ORCID iD | https://orcid.org/0000-0003-2362-3094 |
| Works | 1,200 |

## Researcher papers

- [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/)
- [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/)
- [Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression](https://scholariq.org/papers/metastasis-is-regulated-via-microrna-200-zeb1-axis-control-of-tumour-cell-pd-l1/)
- [Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer](https://scholariq.org/papers/targeting-dna-damage-response-promotes-antitumor-immunity-through-sting-mediated/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition](https://scholariq.org/papers/a-patient-derived-pan-cancer-emt-signature-identifies-global-molecular/)
- [CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade](https://scholariq.org/papers/cd38-mediated-immunosuppression-as-a-mechanism-of-tumor-cell-escape-from-pd-1-pd/)
- [Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC](https://scholariq.org/papers/comutations-and-krasg12c-inhibitor-efficacy-in-advanced-nsclc/)
- [Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i> -Mutant Lung Cancer](https://scholariq.org/papers/metabolic-and-functional-genomic-studies-identify-deoxythymidylate-kinase-as-a/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.